Treatment patterns with topicals, traditional systemics and biologics in psoriasis - A Swedish database analysis

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 2, 2015, Pages 215-223

  Svedbom, A ^a,b   Dalen J ^a   Mamolo, C ^c   Cappelleri, J C ^c   Petersson, I F ^d   Stahle M ^b  

^a OptumInsight   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c PFIZER INC   (United States)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; BETAMETHASONE; CALCIPOTRIOL; ETANERCEPT; ETRETIN; METHOTREXATE; MOMETASONE FUROATE; USTEKINUMAB; BIOLOGICAL PRODUCT;

ADULT; ARTICLE; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; SWEDEN; MIDDLE AGED; REGISTER; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; BIOLOGICAL PRODUCTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PSORIASIS; REGISTRIES; SWEDEN;

EID: 84921507225     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12494     Document Type: Article

References (26)

1. Menter A, Gottlieb A, Feldman SR, et al,. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58: 826-850.
2. Barzi S, Befrits G, Bergman B, et al,. Läkemedelsbehandling av psoriasis-ny rekommendation. Information from the Medical Products Agency, 2011.
3. Baer AH, Khanna V, Feldman SR,. Literature is lacking in discussion of non-adherence in dermatology. J Dermatolog Treat 2010; 21: 109-110.
4. Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR,. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. J Dermatolog Treat 2013; 24: 25-33.
5. Bonafede M, Fox KM, Watson C, Princic N, Gandra SR,. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther 2012; 29: 664-674.
6. Feldman SR, Evans C, Russell MW,. Systemic treatment for moderate to severe psoriasis: estimates of failure rates and direct medical costs in a north-eastern US managed care plan. J Dermatolog Treat 2005; 16: 37-42.
7. Gniadecki R, Kragballe K, Dam TN, Skov L,. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris. Br J Dermatol 2011; 164: 1091-1096.
8. Khalid JM, Fox KM, Globe G, Maguire A, Chau D,. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England. J Dermatolog Treat 2013; 25: 67-72.
9. Esposito M, Gisondi P, Cassano N, et al,. Survival rate of antitumour necrosis factor-alpha treatments for psoriasis in routine dermatological practice: a multicentre observational study. Br J Dermatol 2013; 169: 666-672.
10. Statistics Sweden. Population statistics. [WWW document] 2013. http://www.scb.se/ (last accessed: 30 April 2013).
11. Molin R, Johansson L,. Swedish Health Care in an International Context-a comparison of care needs, costs, and outcomes. Report from the Swedish Association of Local Authorities and Regions (SALAR), 2005.
12. The Dental and Pharmaceutical Benefits Agency. The Swedish high cost threshold. [WWW document] 2013. http://www.tlv.se/in-english-old/medicines-new/the-swedish-high-cost-threshold/how-it-works/ (last accessed: 15 March 2013).
13. Haglund E, Bremander AB, Petersson IF, et al,. Prevalence of spondyloarthritis and its subtypes in southern Sweden. Ann Rheum Dis 2011; 70: 943-948.
14. Wettermark B, Hammar N, Fored CM, et al,. The new Swedish Prescribed Drug Register-opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007; 16: 726-735.
15. National Board of Health and Welfare. The causes of death register. [WWW document] 2013. http://www.socialstyrelsen.se/register/dodsorsaksregistret/ (last accessed: 30 April 2013).
16. Statistics Sweden. The total population register. [WWW document] 2013. http://www.scb.se/sv-/Vara-tjanster/SCBs-data-for-forskning/SCBs-datalager/Registret-over-totalbefolkningen-RTB/ (last accessed: 30 April 2013).
17. Lunde AS, Lundeborg S, Lettenstrom GS, Thygesen L, Huebner J,. The person-number systems of Sweden, Norway, Denmark, and Israel. Vital Health Stat 2 1980; 84: 1-59.
18. Gustavsson A, Bjorkman J, Ljungcrantz C, et al,. Socio-economic burden of patients with a diagnosis related to chronic pain-register data of 840,000 Swedish patients. Eur J Pain 2012; 16: 289-299.
19. Hubertsson J, Petersson IF, Thorstensson CA, Englund M,. Risk of sick leave and disability pension in working-age women and men with knee osteoarthritis. Ann Rheum Dis 2013; 72: 401-405.
20. National Board of Health and Welfare. Läkemedelsregistret-Bortfall och Kvalitet. [WWW document] 2013. http://www.socialstyrelsen.se/register/halsodataregister/lakemedelsregistret/bortfallochkvalitet (last accessed: 30 April 2013).
21. Cramer JA, Roy A, Burrell A, et al,. Medication compliance and persistence: terminology and definitions. Value Health 2008; 11: 44-47.
22. Kaplan E, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Brookmeyer R, Crowley J,. A confidence interval for the median survival time. Biometrics 1982; 38: 29-41.
24. Hosmer D, Lemeshow S, May S,. Applied Survival Analysis, 2nd edn. John Wiley & Sons, New York, 2008.
25. van Cranenburgh OD, de Korte J, Sprangers MA, de Rie MA, Smets EM,. Satisfaction with treatment among patients with psoriasis: a web-based survey study. Br J Dermatol 2013; 169: 398-405.
26. Ragnarson TG, Hjortsberg C, Bjarnason A, et al,. Treatment patterns, treatment satisfaction, severity of disease problems, and quality of life in patients with psoriasis in three Nordic countries. Acta Derm Venereol 2012; 93: 442-445.